Imexpharm (STC:IMP) Total Liabilities : ₫666,801 Mil (As of Mar. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Imexpharm Total Liabilities?

Imexpharm's Total Liabilities for the quarter that ended in Mar. 2025 was ₫666,801 Mil.

Imexpharm's quarterly Total Liabilities declined from Sep. 2024 (₫431,591.48 Mil) to Dec. 2024 (₫321,657.50 Mil) but then increased from Dec. 2024 (₫321,657.50 Mil) to Mar. 2025 (₫666,800.66 Mil).

Imexpharm's annual Total Liabilities declined from Dec. 2022 (₫382,496.68 Mil) to Dec. 2023 (₫308,036.21 Mil) but then increased from Dec. 2023 (₫308,036.21 Mil) to Dec. 2024 (₫321,657.50 Mil).

Imexpharm Total Liabilities Historical Data

The historical data trend for Imexpharm's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imexpharm Total Liabilities Chart

Imexpharm Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

365,969.10

500,290.19

382,496.68

308,036.21

321,657.50

Imexpharm Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															326,847.25	427,328.10	431,591.48	321,657.50	666,800.66

Imexpharm Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Imexpharm's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	321657.498	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	321,657

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	2504776.667	-	2183119.169
	=	321,657

Imexpharm's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	409800.663	+	(250000	+	-5.8207660913467E-11
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	666,801

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	2914380.964	-	2247580.302
	=	666,801

Imexpharm Total Liabilities Related Terms

Thank you for viewing the detailed overview of Imexpharm's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Imexpharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Imexpharm Corp (STC:IMP) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM

Website

http://www.imexpharm.com

Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. Its products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.

Imexpharm Headlines

No Headlines